ALLG trials BM12, CML12 and LS21 accepted to European Hematology Association (EHA) 2022

The ALLG trial BM12 CAST has been accepted for publication as an abstract at EHA. Congratulations to the Chief Investigators A/Prof David Curtis and Dr Sushrut Patil, and the trial team. This is a randomised clinical trial looking at a new way of preventing a serious complication of transplant called graft versus host disease or GVHD; in particular looking at whether a post-transplant treatment drug [cyclophosphamide] is better than standard of care to prevent GVHD and can improve long-term outcomes including quality of life. BM12 is the only randomised study to address this question.

The ALLG CML12 DIRECT trials’ abstract has been accepted to EHA 2022. Congratulations to Chief Investigator Dr David Yeung and the trial team. This trial studies the use of a drug called Dasatinib in Chronic myeloid leukaemia (CML), a type of cancer that affects the blood and bone marrow, and is specific for ‘Chronic Phase’ patients aged >60 years.

The LS21 poster has been accepted to EHA2022. We congratulate Chief Investigator Dr Gareth Gregory and the team. This is for Uncommon Lymphoma: A Biomarker Study in Marginal zone lymphoma patients treated with a BTK inhibitor. This project studied patients with relapsed marginal zone lymphoma; a rare and incurable form of non-Hodgkin lymphoma. They were on a clinical trial of a new targeted treatment, and this study is assessing genetic aspects of the patients’ lymphoma to see if they can predict who will and won’t benefit from this treatment.

Standard of care for this condition is usually with different types of chemotherapy from what the patient has had before. Patients that have relapsed after standard therapy have few options and there are no good predictors of response to targeted treatment. This is a targeted treatment that is not chemotherapy, but rather targets an enzyme (type of protein) in the lymphoma cells that they depend on. The study is expected to provide some guidance as to which patients with marginal zone lymphoma might benefit from the new treatment.

Congratulations to the Chief Investigators and trial teams!